Results 11 to 20 of about 59,116 (263)
Frontiers in Pharmacology, 2023 Objectives: Our objective was to analyse effectiveness and safety of oral anticoagulants (OAC) for stroke prevention in non-valvular atrial fibrillation.Material and methods: Population-based cohort study including adults initiating oral anticoagulants ...
Maria Giner-Soriano +18 more
doaj +1 more source
The safety of new oral anticoagulants for ischemic stroke and systemic embolism prevention in females with atrial fibrillation [PDF]
Romanian Journal of Neurology, 2021 The prevalence of atrial fibrillation is lower in females than in men, but the risk of stroke and systemic thromboembolism is comparable or even higher. Administration of anticoagulant therapy does not modify this difference. Two classes of non-vitamin K
Despina-Manuela Toader +3 more
doaj +1 more source
Canadian Medical Association Journal, 2015 A CMAJ letter[1][1] from a “little cheese” family physician about new oral anticoagulants versus warfarin, and the response[2][2] from three “big cheese” academic specialists show that readers and authors of guidelines do not always agree.
Thomas L, Perry +4 more
openaire +2 more sources
Effects of oral anticoagulants on bone health (systematic literature review)
Bolʹ, Sustavy, Pozvonočnik, 2023 Background. Osteoporosis is actually today's problem, as it affects the quality and length of life, and increases the risk of fragility fractures, which leads to significant medical, social, and economic problems.
H.V. Mostbauer +4 more
doaj +1 more source
The new oral anticoagulants [PDF]
Clinical Medicine, 2011 Anticoagulants have been used for over 70 years for prevention and treatment of potentially fatal thromboembolic events. Heparins and vitamin K antagonists have been the mainstay of treatment and, although effective if managed properly, also have significant drawbacks. Unfractionated heparins (UFH)
Breen, K. A., Hunt, B. J.
openaire +3 more sources
PLoS ONE, 2021 BackgroundProton pump inhibitors (PPIs) are known to reduce the risk of upper gastrointestinal bleeding in patients on oral anticoagulants, and patients are increasingly on oral anticoagulants and PPI co-therapy.
Hyun-Jung Lee +7 more
doaj +1 more source
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
Рациональная фармакотерапия в кардиологии, 2022 The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers ...
B. A. Tatarsky, N. V. Kazennova
doaj +1 more source
Oral Anticoagulation Thresholds [PDF]
Circulation, 2001 Background Monitoring patients on oral anticoagulation is essential to prevent hemorrhage and recurrent thrombosis. We studied tissue factor–induced whole-blood coagulation in patients on warfarin therapy with similar international ...
K E, Brummel +3 more
openaire +2 more sources
The new oral anticoagulants [PDF]
Blood, 2010 Abstract Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant ...
David, Garcia +2 more
openaire +5 more sources
Travel and Oral Anticoagulation [PDF]
Journal of Travel Medicine, 2009 Millions of individuals worldwide are on permanent or temporary oral anticoagulation treatment with vitamin K antagonists (VKAs). The effectiveness of VKAs has been established by clinical trials for several indications. Among these, the primary or secondary prevention of venous thromboembolism, the prevention of systemic embolism in patients with ...
Jürgen, Ringwald +2 more
openaire +2 more sources